A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity.
暂无分享,去创建一个
Andrew H. Beck | David M Sabatini | Andrew H Beck | Kuang Shen | A. Beck | D. Sabatini | Kıvanç Birsoy | K. Shen | V. Nardi | Brian C Grabiner | Richard Possemato | Valentina Nardi | Kıvanc Birsoy | Sumi Sinha | Alexander Jordan | Brian C. Grabiner | Sumi Sinha | Richard L. Possemato | Alexa A Jordan
[1] M. Tomita,et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. , 2009, Cancer research.
[2] Laurie D. Smith,et al. Exome Sequencing Reveals De Novo Germline Mutation of the Mammalian Target of Rapamycin (MTOR) in a Patient with Megalencephaly and Intractable Seizures , 2013 .
[3] N. Pavletich,et al. mTOR kinase structure, mechanism and regulation by the rapamycin-binding domain , 2013, Nature.
[4] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[5] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[6] D. Sabatini,et al. DEPTOR Is an mTOR Inhibitor Frequently Overexpressed in Multiple Myeloma Cells and Required for Their Survival , 2009, Cell.
[7] H. Aburatani,et al. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] A. Lustig,et al. Coupling of Glucose Deprivation with Impaired Histone H2B Monoubiquitination in Tumors , 2012, PloS one.
[9] S. Shirasawa,et al. Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA. , 2012, Carcinogenesis.
[10] S. Gabriel,et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.
[11] M. Loda,et al. The oncogenic properties of mutant p110α and p110β phosphatidylinositol 3-kinases in human mammary epithelial cells , 2005 .
[12] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[13] T. Choueiri,et al. Precision medicine for metastatic renal cell carcinoma. , 2014, Urologic oncology.
[14] J. Urano,et al. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells , 2007, Proceedings of the National Academy of Sciences.
[15] Steven J. M. Jones,et al. Complete genomic landscape of a recurring sporadic parathyroid carcinoma , 2013, The Journal of pathology.
[16] D. Sabatini,et al. Amino acids and mTORC 1 : from lysosomes to disease , 2012 .
[17] David Dunson,et al. Genetic heterogeneity of diffuse large B-cell lymphoma , 2013, Proceedings of the National Academy of Sciences.
[18] G. Mills,et al. PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors , 2012, Clinical Cancer Research.
[19] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[20] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[21] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[22] Roberto Zoncu,et al. Amino acids and mTORC1: from lysosomes to disease. , 2012, Trends in molecular medicine.
[23] S. Gabriel,et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly , 2012, Nature Genetics.
[24] A. Nakashima,et al. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer , 2010, Oncogene.
[25] S. Snyder,et al. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[26] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[27] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[28] D. Sabatini,et al. mTOR: from growth signal integration to cancer, diabetes and ageing , 2010, Nature Reviews Molecular Cell Biology.
[29] A. Marks,et al. Rapamycin resistance is linked to defective regulation of Skp2. , 2012, Cancer research.
[30] J. Blenis,et al. Dominant mutations confer resistance to the immunosuppressant, rapamycin, in variants of a T cell lymphoma. , 1995, Cellular immunology.
[31] H. Aburatani,et al. Integrated molecular analysis of clear-cell renal cell carcinoma , 2013, Nature Genetics.
[32] David T. W. Jones,et al. Signatures of mutational processes in human cancer , 2013, Nature.
[33] M. Birtwistle,et al. Novel Somatic Mutations to PI3K Pathway Genes in Metastatic Melanoma , 2012, PloS one.
[34] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[35] Elias Campo Guerri,et al. International network of cancer genome projects , 2010 .
[36] D. Sabatini,et al. Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer. , 2010, Journal of medicinal chemistry.
[37] Li Zhao,et al. Phosphatidylinositol 3-kinase: the oncoprotein. , 2010, Current topics in microbiology and immunology.
[38] Matthew Meyerson,et al. A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That Signal Amino Acid Sufficiency to mTORC1 , 2013, Science.
[39] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[40] M. Loda,et al. The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[41] David M. Sabatini,et al. The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1 , 2008, Science.
[42] M. Hall,et al. Rapamycin passes the torch: a new generation of mTOR inhibitors , 2011, Nature Reviews Drug Discovery.
[43] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[44] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[45] S. Snyder,et al. RAFT 1 phosphorylation of the translational regulators p 70 S 6 kinase and 4 EBP 1 , 1998 .
[46] Robert T. Jones,et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations , 2013, Nature Genetics.